ArticlePhysiological research2026
Association Between Serum SFRP1 Levels and Coronary Artery Calcification in Stage 5D Chronic Kidney Disease Undergoing Maintenance Hemodialysis.
Article in Physiological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to examine the association between serum Secreted Frizzled-Related Protein 1 (SFRP1) levels and the presence of coronary artery calcification (CAC) in patients with Stage 5D chronic kidney disease (CKD) undergoing maintenance hemodialysis (MHD). A case-control study was conducted involving 76 patients with CKD Stage 5D undergoing MHD. Participants were stratified into three groups based on Coronary Artery Calcium Scores (CACS): non-calcified (CACS < 100), low-score calcification (100 ? CACS ? 400), and high-score calcification (CACS > 400). Serum concentrations of SFRP1, hemoglobin, albumin, ferritin, C-reactive protein (CRP), calcium, phosphorus, 25-hydroxyvitamin D, and intact parathyroid hormone were measured. Correlations between biochemical parameters and CAC were evaluated, and multivariate linear regression analysis was employed to identify independent risk factors for CAC. CAC was detected in 60.5 % of the study population. Serum SFRP1 concentrations were significantly elevated in the high-score calcification group compared to both the low-score and non-calcified groups, with the lowest levels observed in the non-calcified group (p < 0.01). Positive correlations were observed between CAC and serum levels of SFRP1 levels, phosphorus, age, hemoglobin, alkaline phosphatase, and age. Multivariate linear regression analysis identified serum SFRP1 and phosphorus levels as independent risk factors for CAC in this population (p < 0.05). Receiver operating characteristic (ROC) curve analysis demonstrated that serum SFRP1 levels yielded an area under the curve (AUC) of 0.898 (95 % CI: 0.826-0.970, p < 0.0001) for predicting CAC, with a Youden index of 0.738 at a cut-off value of 4.242 ng/ml. Elevated serum SFRP1 levels were associated with an increased likelihood of CAC in patients with Stage 5D CKD undergoing MHD. These findings suggest that SFRP1 may represent a potential biomarker for identifying patients at risk for CAC in this population.
Indexed as
Identifiers
42187504PMC13225440What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.